FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308605071> ?p ?o ?g. }

• W4308605071 endingPage "907" @default.
• W4308605071 startingPage "903" @default.
• W4308605071 abstract "Olanzapine pamoate is an intramuscular depot injection for the treatment of schizophrenia. Approximately 1.4% of patients develop a serious adverse event called post-injection delirium/sedation syndrome (PDSS), characterised by drowsiness, anticholinergic and extrapyramidal symptoms. The objective is to investigate olanzapine PDSS presentations including clinical features and treatment approach. This is a retrospective review of olanzapine PDSS patients from three toxicology units and the NSW Poisons Information Centre between 2017 and 2022. Adult patients were included if they had intramuscular olanzapine then developed PDSS criteria. Clinical symptoms, treatment, timing and length of symptoms were extracted into a preformatted Excel database. There were 18 patients included in the series, with a median age of 49 years (interquartile range [IQR]: 38-58) and male predominance (89%). Median onset time post injection was 30 min (IQR: 11-38). PDSS symptoms predominate with drowsiness, confusion and dysarthria. Median length of symptoms was 24 h (IQR: 20-54). Most common treatment included supportive care without any pharmacological intervention (n = 10), benzodiazepine (n = 4) and benztropine (n = 3). In one case, bromocriptine and physostigmine followed by oral rivastigmine were given to manage antidopaminergic and anticholinergic symptoms respectively. This proposed treatment combination could potentially alleviate some of the symptoms but needs further studies to validate the findings. In conclusion, this case series supports the characterisation of PDSS symptomology predominantly being anticholinergic with similar onset (<1 h) and duration (<72 h). Bromocriptine is proposed to manage PDSS if patients develop severe dopamine blockade and physostigmine followed by rivastigmine for anticholinergic delirium." @default.
• W4308605071 created "2022-11-13" @default.
• W4308605071 creator A5010471692 @default.
• W4308605071 creator A5027913534 @default.
• W4308605071 creator A5034739281 @default.
• W4308605071 creator A5063118852 @default.
• W4308605071 creator A5064606443 @default.
• W4308605071 creator A5083642778 @default.
• W4308605071 date "2022-11-20" @default.
• W4308605071 modified "2023-10-16" @default.
• W4308605071 title "Case series profile of olanzapine post‐injection delirium/sedation syndrome" @default.
• W4308605071 cites W1980943686 @default.
• W4308605071 cites W1999778428 @default.
• W4308605071 cites W2008702861 @default.
• W4308605071 cites W2009416404 @default.
• W4308605071 cites W2009915038 @default.
• W4308605071 cites W2077496242 @default.
• W4308605071 cites W2081326987 @default.
• W4308605071 cites W2229407598 @default.
• W4308605071 cites W2279966727 @default.
• W4308605071 cites W2744867315 @default.
• W4308605071 cites W2810509521 @default.
• W4308605071 cites W3087285013 @default.
• W4308605071 cites W3110835287 @default.
• W4308605071 cites W3129153696 @default.
• W4308605071 cites W3199710005 @default.
• W4308605071 cites W3200660426 @default.
• W4308605071 cites W4283823856 @default.
• W4308605071 cites W4308605071 @default.
• W4308605071 doi "https://doi.org/10.1111/bcp.15588" @default.
• W4308605071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36349832" @default.
• W4308605071 hasPublicationYear "2022" @default.
• W4308605071 type Work @default.
• W4308605071 citedByCount "2" @default.
• W4308605071 countsByYear W43086050712022 @default.
• W4308605071 countsByYear W43086050712023 @default.
• W4308605071 crossrefType "journal-article" @default.
• W4308605071 hasAuthorship W4308605071A5010471692 @default.
• W4308605071 hasAuthorship W4308605071A5027913534 @default.
• W4308605071 hasAuthorship W4308605071A5034739281 @default.
• W4308605071 hasAuthorship W4308605071A5063118852 @default.
• W4308605071 hasAuthorship W4308605071A5064606443 @default.
• W4308605071 hasAuthorship W4308605071A5083642778 @default.
• W4308605071 hasBestOaLocation W43086050711 @default.
• W4308605071 hasConcept C118552586 @default.
• W4308605071 hasConcept C126322002 @default.
• W4308605071 hasConcept C187212893 @default.
• W4308605071 hasConcept C197934379 @default.
• W4308605071 hasConcept C2775910092 @default.
• W4308605071 hasConcept C2776332859 @default.
• W4308605071 hasConcept C2776412080 @default.
• W4308605071 hasConcept C2776619155 @default.
• W4308605071 hasConcept C2776663719 @default.
• W4308605071 hasConcept C2776814716 @default.
• W4308605071 hasConcept C2778689640 @default.
• W4308605071 hasConcept C2779134260 @default.
• W4308605071 hasConcept C2779158372 @default.
• W4308605071 hasConcept C2779483572 @default.
• W4308605071 hasConcept C2779753318 @default.
• W4308605071 hasConcept C2780494398 @default.
• W4308605071 hasConcept C2780616385 @default.
• W4308605071 hasConcept C2780904820 @default.
• W4308605071 hasConcept C2910745098 @default.
• W4308605071 hasConcept C42219234 @default.
• W4308605071 hasConcept C71924100 @default.
• W4308605071 hasConceptScore W4308605071C118552586 @default.
• W4308605071 hasConceptScore W4308605071C126322002 @default.
• W4308605071 hasConceptScore W4308605071C187212893 @default.
• W4308605071 hasConceptScore W4308605071C197934379 @default.
• W4308605071 hasConceptScore W4308605071C2775910092 @default.
• W4308605071 hasConceptScore W4308605071C2776332859 @default.
• W4308605071 hasConceptScore W4308605071C2776412080 @default.
• W4308605071 hasConceptScore W4308605071C2776619155 @default.
• W4308605071 hasConceptScore W4308605071C2776663719 @default.
• W4308605071 hasConceptScore W4308605071C2776814716 @default.
• W4308605071 hasConceptScore W4308605071C2778689640 @default.
• W4308605071 hasConceptScore W4308605071C2779134260 @default.
• W4308605071 hasConceptScore W4308605071C2779158372 @default.
• W4308605071 hasConceptScore W4308605071C2779483572 @default.
• W4308605071 hasConceptScore W4308605071C2779753318 @default.
• W4308605071 hasConceptScore W4308605071C2780494398 @default.
• W4308605071 hasConceptScore W4308605071C2780616385 @default.
• W4308605071 hasConceptScore W4308605071C2780904820 @default.
• W4308605071 hasConceptScore W4308605071C2910745098 @default.
• W4308605071 hasConceptScore W4308605071C42219234 @default.
• W4308605071 hasConceptScore W4308605071C71924100 @default.
• W4308605071 hasIssue "2" @default.
• W4308605071 hasLocation W43086050711 @default.
• W4308605071 hasLocation W43086050712 @default.
• W4308605071 hasLocation W43086050713 @default.
• W4308605071 hasOpenAccess W4308605071 @default.
• W4308605071 hasPrimaryLocation W43086050711 @default.
• W4308605071 hasRelatedWork W2026036833 @default.
• W4308605071 hasRelatedWork W2029405936 @default.
• W4308605071 hasRelatedWork W2055683445 @default.
• W4308605071 hasRelatedWork W2070662185 @default.
• W4308605071 hasRelatedWork W2137461746 @default.
• W4308605071 hasRelatedWork W2234857532 @default.

• next